China Pharma Holdings, Inc.(CPHI)

$0.71—Stale · unknown old

Ask SA Chart

China Pharma Holdings, Inc.(CPHI)

NYSE • Last print unknown ago

$0.71—Stale · unknown old

Ask SA Chart Studio

CPHI(CPHI)

CPHI

9/19/26

China Pharma (CPHI)

Saturday

11:09 AM

ThesisThe company continues to struggle with operational efficiency and profitability, leading to a more negative outlook among investors.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$5M	$4M
Rev. Growth	-35.4%	-8.5%
EPS	$-0.27	$-0.74
EPS Growth	+6.9%	-174%
P/E	—	—

What Could Go Wrong

01Declining gross margins due to increased competition may lead to further operational losses, with gross margins expected to dip below -5%.
02Potential regulatory changes in China could impose stricter pricing controls, impacting revenue generation capabilities.
03Regulatory changes impacting drug pricing and approvals
04Technological advancements in drug development by competitors
05Intense competition from both domestic and international generic manufacturers
06Potential entry of large pharmaceutical companies into the generic market
07Negative operating margins leading to liquidity concerns
08Limited cash flow generation affecting operational sustainability

FY2025 Snapshot

Revenue: $4M
Rev. Growth: -8.5%
Gross Margin: -3.2%
Op. Margin: -74.5%
Net Margin: -76.9%
Net Income: $-3M
NI Growth: +32.7%
EPS: $-0.74
1Y Return: -64.1%

CPHI Chart

My Notes

"Management has indicated that 'operational challenges remain a significant hurdle for recovery.'"
Moat: The company's competitive advantage is weak due to high competition and low barriers to entry in the generic drug market.
Watch: The increasing presence of international pharmaceutical giants in the Chinese market poses a significant threat to CPHI's market share.
value - Investors may be drawn to the low valuation metrics, but the company’s operational challenges present risks.
Low - The company is not heavily reliant on debt, and interest rate changes have minimal impact on its financing costs.
Watch on earnings: Market share in the generic drug segment, Regulatory approval timelines for new products, Gross margin percentage.

One Sentence Summary:

The bear case: declining gross margins due to increased competition may lead to further operational losses, with gross margins expected to dip below -5%.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2024

FY2025

P/E

—

What Could Go Wrong

01Declining gross margins due to increased competition may lead to further operational losses, with gross margins expected to dip below -5%.

02Potential regulatory changes in China could impose stricter pricing controls, impacting revenue generation capabilities.

03Regulatory changes impacting drug pricing and approvals

04Technological advancements in drug development by competitors

05Intense competition from both domestic and international generic manufacturers

06Potential entry of large pharmaceutical companies into the generic market

07Negative operating margins leading to liquidity concerns

08Limited cash flow generation affecting operational sustainability

My Notes

"Management has indicated that 'operational challenges remain a significant hurdle for recovery.'"

Moat: The company's competitive advantage is weak due to high competition and low barriers to entry in the generic drug market.

Watch: The increasing presence of international pharmaceutical giants in the Chinese market poses a significant threat to CPHI's market share.

value - Investors may be drawn to the low valuation metrics, but the company’s operational challenges present risks.

Low - The company is not heavily reliant on debt, and interest rate changes have minimal impact on its financing costs.

Watch on earnings: Market share in the generic drug segment, Regulatory approval timelines for new products, Gross margin percentage.